Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Quantitative real time PCR (RT-PCR) is widely used as the gold standard for clinical
detection of SARS-CoV-2. However, due to the low viral load specimens and the limitations …

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in
various body effluents such as blood or urine instead of a fragment of cancer tissue. It is …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Cancer is a major global health burden and poor survival rates can be attributed to lack of
early diagnosis and limited access to timely and standard treatments. Significant progress …

PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic colorectal
cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is …

Digital nucleic acid detection based on microfluidics technology can quantify the initial
amount of nucleic acid in the sample with low equipment requirements and simple …

Detecting cancer biomarkers (eg, circulating tumor cells, extracellular vehicles, nucleic
acids, and protein biomarkers) is vital for risk assessment and early diagnosis. Nanomaterial …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …